ArticleFrontiers in microbiology2025
Gut microbiome and serum metabolome alterations in osteosarcoma patients.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiota metabolites drive osteosarcoma progression through JUP activation: a multi-omics mendelian randomization study.AMB Express · 2026Article
- Metabolites and Immune Cells Mediated the Causal Relationship Between the Gut Microbiota and Osteosarcoma: A Mendelian Randomization Study.Health science reports · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota has been shown to initiate tumorigenesis and cancer metastasis in multiple cancer types. However, the functional alterations of gut microbiota and their association with metabolism in osteosarcoma patients remain largely unexplored. This study aimed to characterize the gut microbiota and serum metabolite profiles in osteosarcoma patients, evaluate the diagnostic potential of gut microbiota and serum metabolites for osteosarcoma, and explore their correlations. Methods: We collected 128 fecal and 181 serum samples from osteosarcoma patients, paired with matched healthy controls. 16S rRNA sequencing and untargeted metabolomics were applied to analyze gut microbiota and serum metabolism with significantly altered abundance in patients with osteosarcoma. Models based on gut microbiome or serum metabolites were established and evaluated in an independent validation cohort. Results: The gut microbial diversity decreased in osteosarcoma patients compared to healthy individuals. Principal component analysis identified 33 microbial species that exhibited significant changes in osteosarcoma patients. Of note, the relative abundance of Conclusion: This study thoroughly analyzed gut microbiota and serum metabolites in osteosarcoma patients, exploring their correlations and facilitating the establishment of a diagnostic model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.